The inhibition of hepatitis B virus by APOBEC cytidine deaminases

Journal of Viral Hepatitis

Volumn 20, Issue 12, 2013, Pages 821-828

  Janahi, E M ^a   McGarvey, M J ^b  

^a UNIVERSITY OF BAHRAIN   (Bahrain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

APOBEC; deamination; HBV; replication

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; CYTIDINE; CYTIDINE DEAMINASE; INTERFERON; UNCLASSIFIED DRUG; URACIL; VIRUS DNA;

CELL TRANSFORMATION; DNA STRAND; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CAPSID; VIRUS INHIBITION; VIRUS REPLICATION;

APOBEC; DEAMINATION; HBV; REPLICATION;

CYTIDINE DEAMINASE; DNA, VIRAL; HEPATITIS B VIRUS; HUMANS; RNA, VIRAL;

EID: 84887561086     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12192     Document Type: Review

References (61)

1. Navaratnam N, Morrison JR, Bhattacharya S, et al,. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 1993; 268: 20709-20712.
2. Jarmuz A, Chester A, Bayliss J, et al,. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002; 79: 285-296.
3. Liao W, Hong SH, Chan BH, Rudolph FB, Clark SC, Chan L,. APOBEC2 a cardiac and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem Biophys Res Commun 1999; 260: 398-404.
4. Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV,. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 2005; 4: 1281-1285.
5. Gabuzda DH, Li H, Lawrence K, Vasir BS, Crawford K, Langhoff E,. Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/macrophages. J Acquir Immune Defic Syndr 1994; 7: 908-915.
6. + T-cell lines. Virus Res 1994; 33: 269-280.
7. Sheehy AM, Gaddis NC, Choi JD, Malim MH,. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
8. Wedekind JE, Dance GS, Sowden MP, Smith HC,. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet 2003; 19: 207-216.
9. Hultquist JF, Lengyel JA, Refsland EW, et al,. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 2011; 85: 11220-11234.
10. Schmitt K, Guo K, Algaier M, et al,. Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology 2011; 419: 24-42.
11. Bransteitter R, Pham P, Scharff MD, Goodman MF,. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc Natl Acad Sci USA 2003; 100: 4102-4107.
12. Okuyama S, Marusawa H, Matsumoto T, et al,. Excessive activity of apolipoprotein B mRNA editing enzyme catalytic polypeptide 2 (APOBEC2) contributes to liver and lung tumorigenesis. Int J Cancer 2012; 130: 1294-1301.
13. Alce TM, Popik W,. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 2004; 279: 34083-34086.
14. Schafer A, Bogerd HP, Cullen BR,. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004; 328: 163-168.
15. Berkowitz RD, Ohagen A, Hoglund S, Goff SP,. Retroviral nucleocapsid domains mediate the specific recognition of genomic viral RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J Virol 1995; 69: 6445-6456.
16. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D,. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424: 99-103.
17. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L,. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424: 94-98.
18. Harris RS, Bishop KN, Sheehy AM, et al,. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-809.
19. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR,. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J Virol 2005; 79: 10978-10987.
20. Yu Q, Konig R, Pillai S, et al,. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004; 11: 435-442.
21. Cullen BR,. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 2006; 80: 1067-1076.
22. Chen H, Lilley CE, Yu Q, et al,. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 2006; 16: 480-485.
23. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR,. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res 2006; 34: 89-95.
24. Bogerd HP, Wiegand HL, Hulme AE, et al,. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA 2006; 103: 8780-8785.
25. Schmitz A, Schwarz A, Foss M, et al,. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog 2010; 6: e1000741.
26. Newbold JE, Xin H, Tencza M, et al,. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69: 3350-3357.
27. Nassal M, Hepatitis B,. Viruses: reverse transcription a different way. Virus Res 2008; 134: 235-249.
28. Turelli P, Mangeat B, Jost S, Vianin S, Trono D,. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303: 1829.
29. Li D, Liu J, Kang F, et al,. Core-APOBEC3C chimerical protein inhibits hepatitis B virus replication. J Biochem 2011; 150: 371-374.
30. Rosler C, Kock J, Malim MH, Blum HE, von WF,. Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science 2004; 305: 1403.
31. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP,. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 8321-8326.
32. Noguchi C, Ishino H, Tsuge M, et al,. G to A hypermutation of hepatitis B virus. Hepatology 2005; 41: 626-633.
33. Kock J, Blum HE,. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89: 1184-1191.
34. Bonvin M, Achermann F, Greeve I, et al,. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-1374.
35. Noguchi C, Hiraga N, Mori N, et al,. Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 2007; 88: 432-440.
36. Lei YC, Tian YJ, Ding HH, et al,. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication. World J Gastroenterol 2006; 12: 7488-7496.
37. Lei YC, Hao YH, Zhang ZM, et al,. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol 2006; 12: 4492-4497.
38. Zhang T, Cai J, Chang J, et al,. Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma. Hum Mol Genet 2013; 22: 1262-1269.
39. Bonvin M, Greeve J,. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro. J Gen Virol 2007; 88: 3270-3274.
40. Henry M, Guetard D, Suspene R, Rusniok C, Wain-Hobson S, Vartanian JP,. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS ONE 2009; 4: e4277.
41. Nguyen DH, Gummuluru S, Hu J,. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007; 81: 4465-4472.
42. Zhang W, Zhang X, Tian C, et al,. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol 2008; 10: 112-121.
43. Rosler C, Kock J, Kann M, et al,. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005; 42: 301-309.
44. Nguyen DH, Hu J,. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008; 82: 6852-6861.
45. Zhao D, Wang X, Lou G, et al,. APOBEC3G directly binds Hepatitis B virus core protein in cell and cell free systems. Virus Res 2010; 151: 213-219.
46. Tanaka Y, Marusawa H, Seno H, et al,. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 2006; 341: 314-319.
47. Jost S, Turelli P, Mangeat B, Protzer U, Trono D,. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol 2007; 81: 10588-10596.
48. Proto S, Taylor JA, Chokshi S, Navaratnam N, Naoumov NV,. APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication. Antiviral Res 2008; 78: 260-267.
49. Chen H, Wang LW, Huang YQ, Gong ZJ,. Interferon-alpha Induces High Expression of APOBEC3G and STAT-1 in Vitro and in Vivo. Int J Mol Sci 2010; 11: 3501-3512.
50. Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, Yamada A,. High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol 2006; 37: 327-332.
51. Vartanian JP, Henry M, Marchio A, et al,. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6: e1000928.
52. Turelli P, Liagre-Quazzola A, Mangeat B, Verp S, Jost S, Trono D,. APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol 2008; 82: 6585-6590.
53. Gonzalez MC, Suspene R, Henry M, Guetard D, Wain-Hobson S, Vartanian JP,. Human APOBEC1 cytidine deaminase edits HBV DNA. Retrovirology 2009; 6: 96.
54. Renard M, Henry M, Guetard D, Vartanian JP, Wain-Hobson S,. APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo. J Mol Biol 2010; 400: 323-334.
55. Liang G, Kitamura K, Wang Z, et al,. RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proc Natl Acad Sci USA 2013; 110: 2246-2251.
56. Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu XF,. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology 2007; 46: 1810-1820.
57. Kidd JM, Newman TL, Tuzan E, Kaul R, Eichler EE,. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007; 3: e63.
58. Abe H, Ochi H, Maekawa T, et al,. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. Hepatol Res 2009; 39: 1159-1168.
59. Xu Ezzikouri S, Kitab B, Rebbani A, et al,. Polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population. J Vir Hep 2007; 20: 678-686.
60. An P, Blieber G, Duggal P, et al,. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004; 78: 11070-11076.
61. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, Muramatsu M,. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog 2013; 9: e1003361.